Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 26

PMID 39457081

Authors

Vincenzo Quagliariello

Maria Laura Canale

Irma Bisceglia

Martina Iovine

Vienna Giordano

Ilaria Giacobbe

Marino Scherillo

Domenico Gabrielli

Carlo Maurea

Matteo Barbato

Alessandro Inno

Massimiliano Berretta

Andrea Tedeschi

Stefano Oliva

Alessandra Greco

Nicola Maurea

Affiliations

Soon will be listed here.

Abstract

Cancer patients, especially long cancer survivors, are exposed to several cardio-metabolic diseases, including diabetes, heart failure, and atherosclerosis, which increase their risk of cardiovascular mortality. Therapy with glucagon-like peptide 1 (GLP1) receptor agonists demonstrated several beneficial cardiovascular effects, including atherosclerosis and heart failure prevention. Cardiovascular outcome trials (CVOTs) suggest that GLP-1 RA could exert cardiorenal benefits and systemic anti-inflammatory effects in patients with type-2 diabetes through the activation of cAMP and PI3K/AkT pathways and the inhibition of NLRP-3 and MyD88. In this narrative review, we highlight the biochemical properties of GLP-1 RA through a deep analysis of the clinical and preclinical evidence of the primary prevention of cardiomyopathies. The overall picture of this review encourages the study of GLP-1 RA in cancer patients with type-2 diabetes, as a potential primary prevention strategy against heart failure and atherosclerosis.

References

Takeshita Y, Kita Y, Tanaka T, Goto H, Nakano Y, Teramura C . Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study. J Diabetes Investig. 2022; 13(6):965-974. PMC: 9153847. DOI: 10.1111/jdi.13749. View

Wang L, Wang W, Kaelber D, Xu R, Berger N . GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. JAMA Oncol. 2023; 10(2):256-258. PMC: 10704339. DOI: 10.1001/jamaoncol.2023.5573. View

Chen X, Huang Q, Feng J, Xiao Z, Zhang X, Zhao L . GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway. J Int Med Res. 2021; 49(2):300060521992981. PMC: 7917887. DOI: 10.1177/0300060521992981. View

van Bloemendaal L, Ten Kulve J, la Fleur S, IJzerman R, Diamant M . Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2013; 221(1):T1-16. DOI: 10.1530/JOE-13-0414. View

de Oliveira Almeida G, Nienkotter T, Almeida Balieiro C, Pasqualotto E, Cintra J, Carvalho H . Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs. 2024; 24(4):509-521. DOI: 10.1007/s40256-024-00647-3. View

Liu F, Yang Q, Zhang H, Zhang Y, Yang G, Ban B . The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: A meta-analysis of randomised controlled trials. PLoS One. 2022; 17(7):e0270899. PMC: 9262225. DOI: 10.1371/journal.pone.0270899. View

Bethel M, Mentz R, Merrill P, Buse J, Chan J, Goodman S . Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2019; 43(2):446-452. PMC: 7411285. DOI: 10.2337/dc19-1065. View

Mohamed Iqbal A, Imamudeen N, Basheer A, Menon S, Mohan G, Sani T . Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues. Curr Drug Saf. 2020; 16(2):197-206. DOI: 10.2174/1574886315999201208212356. View

Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

10.

Petrie M, Borlaug B, Butler J, Davies M, Kitzman D, Shah S . Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. J Am Coll Cardiol. 2024; 84(1):27-40. DOI: 10.1016/j.jacc.2024.04.022. View

11.

Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R . GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int J Mol Sci. 2023; 24(2). PMC: 9865319. DOI: 10.3390/ijms24021703. View

12.

Vulcan A, Manjer J, Ohlsson B . High blood glucose levels are associated with higher risk of colon cancer in men: a cohort study. BMC Cancer. 2017; 17(1):842. PMC: 5727949. DOI: 10.1186/s12885-017-3874-4. View

13.

Tamai Y, Fujiwara N, Tanaka T, Mizuno S, Nakagawa H . Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2023; 15(20). PMC: 10605879. DOI: 10.3390/cancers15205072. View

14.

Kaneto H, Kimura T, Shimoda M, Obata A, Sanada J, Fushimi Y . Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: "The Earlier, the Better" in Therapy with Incretin-Based Medicine. Int J Mol Sci. 2021; 22(15). PMC: 8348147. DOI: 10.3390/ijms22157917. View

15.

Verma S, McGuire D, Bain S, Bhatt D, Leiter L, Mazer C . Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020; 22(12):2487-2492. PMC: 7754406. DOI: 10.1111/dom.14160. View

16.

Piccoli G, Mesquita L, Stein C, Aziz M, Zoldan M, Degobi N . Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2020; 106(3):912-921. DOI: 10.1210/clinem/dgaa891. View

17.

Lyon A, Yousaf N, Battisti N, Moslehi J, Larkin J . Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018; 19(9):e447-e458. DOI: 10.1016/S1470-2045(18)30457-1. View

18.

Hernandez A, Green J, Janmohamed S, DAgostino Sr R, Granger C, Jones N . Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157):1519-1529. DOI: 10.1016/S0140-6736(18)32261-X. View

19.

Krieger J, da Conceicao E, Sanchez-Watts G, Arnold M, Pettersen K, Mohammed M . Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats. Am J Physiol Regul Integr Comp Physiol. 2018; 315(4):R708-R720. PMC: 6230883. DOI: 10.1152/ajpregu.00068.2018. View

20.

Elnour A, Al Hajri N, Yousif El Khidir I, AlAmoodi A, Ahmed S, Sadeq A . Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review. Curr Diabetes Rev. 2020; 16(8):820-832. DOI: 10.2174/1573399816666200522214554. View